TMR-IR: The effect of memory reactivation during sleep on the reprocessing of distressing Memories in healthy participants and PTSD (posttraumatic stress disorder) patients

TMR-IR: The effect of memory reactivation during sleep on the reprocessing of distressing Memories in healthy participants and PTSD (posttraumatic stress disorder) patients - TMR-IR

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026210

Enrollment

Registered

2021-11-19

Start date

2021-04-16

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F43.1

Interventions

Group 1: congruent odour during nightsleep and psychotherapie sessions (reactivation) Group 2: incongruent odour during nightsleep and psychotherapie sessions (no reactivation)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: -current main diagnosis: PTSD -sufficient stability and patient feels prepared for emotion-activating therapy -motivational and organisational ressources (for 12 sessions, weekly à 90min within a maximum of 16 weeks) -fluency in German language -IQ > 80 -age 18-60

Exclusion criteria

Exclusion criteria: -odour disturbances (e.g. allergies, Post-Covid) -pronounced sleep disturbances, that have been originated before traumatisation, shift work, time zone change, sleep apnoe -alcohol/drug abuse or addiction -medication that is not in line with trauma therapy, e.g. benzodiazepines, opiates -neurological diseases (e.g.: epilepsia), history of brain damage (e.g.: concussion with lost of consciousness) or degenerative neurological disease (e.g. Parkinson, Dementia) -comorbid psychotic disease, comorbid bipolar-I disease (current or in history) -acute suizidality -PTSD-therapy in history (=more than 2 sessions of IR)

Design outcomes

Primary

Measure	Time frame
Clinical Diagnostic of PTSD (CAPS, LEC-5) and Sleep quality (PSQI) at three time points: T0 (before begin of therapy), T1 (after the end of therapy/12 sessions within 12-16 weeks and T2 (6 months after the end of therapy) Follow-up diagnostics PTSD: PCL-5, PTCI and sleep quality by a sleep protocol (at all 12 sessions during therapy, between T0 and T1)	—

Secondary

Measure	Time frame
Differential diagnostic for PTSD, depression (BDI-2), anxiety (BAI) and Self-Efficacy (SWE) at three time points: T0 (before begin of therapy), T1 (after the end of therapy/12 sessions within 12-16 weeks and T2 (6 months after the end of therapy)	—

Countries

Germany

Contacts

Public ContactInes Wilhelm-Groch

UKSH Schleswig-Holstein, Campus Lübeck

Ines.Wilhelm-Groch@uksh.de0049-451-50098892

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026